The Xerostomia drugs in development market research report provides comprehensive information on the therapeutics under development for Xerostomia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Xerostomia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Xerostomia and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Xerostomia by ten companies/universities/institutes. The top development phase for Xerostomia is phase ii with three drugs in that stage. The Xerostomia pipeline has ten drugs in development by companies and one by universities/ institutes. Some of the companies in the Xerostomia pipeline products market are: BioCurity Pharmaceuticals, MeiraGTx and Lubris Biopharma.
The key targets in the Xerostomia pipeline products market include Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM), and Aquaporin 1 (Urine Water Channel or Water Channel Protein For Red Blood Cells And Kidney Proximal Tubule or AQP1).
The key mechanisms of action in the Xerostomia pipeline product include Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Agonist with two drugs in Discovery. The Xerostomia pipeline products include eight routes of administration with the top ROA being Oral and four key molecule types in the Xerostomia pipeline products market including Cell Therapy, and Small Molecule.
Xerostomia overview
Xerostomia is defined as dry mouth resulting from reduced saliva flow. It is caused by medications, age, cancer treatment, injury, dehydration, and chewing or smoking tobacco. Symptoms include dysgeusia, fungal infections, bad breath, tongue ulcers, problems speaking, and sticky saliva. Treatment includes medications that stimulate saliva production.
For a complete picture of Xerostomia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
